Compare · AKCA vs VIE
AKCA vs VIE
Side-by-side comparison of Akcea Therapeutics, Inc. (AKCA) and Viela Bio, Inc. (VIE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AKCA and VIE operate in Major Pharmaceuticals (Health Care), so they compete in similar markets.
- Company
- Akcea Therapeutics, Inc.
- Viela Bio, Inc.
- Price
- -
- -
- Market cap
- -
- -
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Major Pharmaceuticals
- Major Pharmaceuticals
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- 2019
- News (4w)
- 0
- 0
- Recent ratings
- 0
- 0
Latest AKCA
- Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors
- IMPORTANT SHAREHOLDER ALERT: Halper Sadeh LLP Reminds Shareholders About Its Ongoing Investigations; Investors are Encouraged to Contact the Firm - AKCA, BLDR, DCOM, STND
- SHAREHOLDER ALERT: WeissLaw LLP Reminds AKCA, IMMU, and MXIM Shareholders About Its Ongoing Investigations
- Lifshitz Law Firm, P.C. Announces Investigation of Akcea Therapeutics, Inc. (NASDAQ: AKCA), BMC Stock Holdings, Inc. (NASDAQ: BMCH), Builders FirstSource, Inc. (NASDAQ: BLDR), Cancer Genetics, Inc. (NASDAQ: CGIX), Cellular Biomedicine Group, Inc. (NASDAQ: CBMG), Otelco Inc. (NASDAQ: OTEL), Rosetta Stone Inc. (NYSE: RST), Varian Medical Systems, Inc. (NYSE: VAR), and Yintech Investment Holdings Limited (NASDAQ: YIN)
- Moore Kuehn Encourages RST, AKCA, DCOM, and SBPH Investors to Contact Law Firm
- WAYLIVRA▼® (volanesorsen), the First and Only Therapy for FCS, an Ultra-Rare and Life-Threatening Condition, to Be Available on the NHS in England
- Lifshitz Law Firm, P.C. Announces Investigation of Aimmune Therapeutics, Inc., (NASDAQ:AIMT), Akcea Therapeutics, Inc., (NASDAQ:AKCA), BMC Stock Holdings, Inc., (NASDAQ:BMCH), and Cancer Genetics, Inc., (NASDAQ:CGIX)
- INVESTIGATION ALERT: Halper Sadeh LLP Is Investigating the Following Mergers; Shareholders are Encouraged to Contact the Firm – RST, CBMG, AIMT, AKCA
Latest VIE
- SEC Form 15-12B filed by Viela Bio, Inc.
- SEC Form SC 13D/A filed by Viela Bio, Inc.
- SEC Form 4: Yanling Cao disposed to the issuer $441,084,709 worth of Common Stock (8,322,353 units at $53.00)
- SEC Form 4 filed by Tyrell Rivers
- SEC Form 4 filed by Plc Astrazeneca
- SEC Form 4: Andreas Wicki disposed to the issuer $92,750,000 worth of Common Stock (1,750,000 units at $53.00)
- SEC Form 4: Edward Hu disposed to the issuer $220,542,381 worth of Common Stock (4,161,177 units at $53.00)
- SEC Form 4 filed by Ltd Meadow Boundless
- SEC Form 4: Mitchell Chan disposed to the issuer $1,987,500 worth of Common Stock (37,500 units at $53.00), decreasing direct ownership by 100% to 0 units
- SEC Form 4: Jorn Drappa disposed to the issuer $10,741,033 worth of Common Stock (202,661 units at $53.00), decreasing direct ownership by 100% to 0 units